Biogen Inc. (BIT:1BIIB)

Market Cap	23.31B +12.9%
Revenue (ttm)	8.42B +2.2%
Net Income	1.10B -20.8%
EPS	7.49 -21.4%
Shares Out	n/a
PE Ratio	21.17
Forward PE	12.03
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12
Average Volume	43
Open	160.70
Previous Close	165.20
Day's Range	160.70 - 162.65
52-Week Range	99.46 - 171.85
Beta	n/a
RSI	65.00
Earnings Date	Feb 6, 2026

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1978
• Employees: 7,605
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1BIIB

Financial Performance

In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.

Financial numbers in USD